-
Mylan completes acquisition of Agila from Strides Arcolab
PITTSBURGH — Mylan has completed its acquisition of the injectables business of Strides Arcolab, a deal worth nearly $2 billion, the drug maker said.
Mylan said the acquisition of Agila could cost up to $1.75 billion, including a $250 million contingent consideration. As part of the acquisition, Mylan will gain full commercialization rights for most of Agila's U.S. portfolio of experimental and marketed products, including cancer drugs, as well as significant product rights in Canada, Australia, Brazil, Japan and South Korea.
-
Reports: Drug industry organizations sue Seattle-area county government over drug-disposal ordinance
NEW YORK — Four drug industry trade groups are suing the board of health in King County, Wash., over a local health ordinance that they say shifts the burden of sustainable disposal of unwanted drugs onto drug companies, according to published reports.